Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Journal
The Lancet. Oncology
Journal Volume
13
Journal Issue
1
Pages
100
Date Issued
2012-01
Author(s)
Wheeler, Cosette M
Castellsagué, Xavier
Garland, Suzanne M
Szarewski, Anne
Paavonen, Jorma
Naud, Paulo
Salmerón, Jorge
Apter, Dan
Kitchener, Henry
Teixeira, Júlio C
Skinner, S Rachel
Jaisamrarn, Unnop
Limson, Genara
Romanowski, Barbara
Aoki, Fred Y
Schwarz, Tino F
Poppe, Willy A J
Bosch, F Xavier
Harper, Diane M
Huh, Warner
Hardt, Karin
Zahaf, Toufik
Descamps, Dominique
Struyf, Frank
Dubin, Gary
Lehtinen, Matti
Abstract
We evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis after 4 years of follow-up in PATRICIA (PApilloma TRIal against Cancer In young Adults).
Subjects
HUMAN-PAPILLOMAVIRUS INFECTION; MAJOR CAPSID PROTEIN; PARTICLE VACCINE; YOUNG-WOMEN; CANCER; NEOPLASIA; EPITOPES; IMPACT; RISK; IDENTIFICATION
Publisher
ELSEVIER SCIENCE INC
Type
journal article